Nuclear Medicine Therapy

  Prostate Cancer , according to the World Cancer Research Fund, is not only one of the most common malignancy in men, but also one of the most commonly occurring cancer overall. The incidence of prostate cancer increases proportionally with age, especially in men above 60 years of age. For advanced prostate cancer patients or metastatic castration-resistant prostate cancer (mCRPC) patients, conventional treatment modalities, such as surgery, chemotherapy etc. might not prove to be highly effective in terms of controlling the spread of the cancer. This is where Nuclear Medicine and Molecular Imaging are playing an important part in the management of cancer and that too in a personalized manner. Several nuclear medicine clinics around world have confirmed that there is now a new hope for metastatic castrate-resistant prostate cancer (mCRPC) patients –  Targeted Alpha Therapy of Alpha PSMA   Therapy using radiolabeled PSMA inhibitors or alpha-emitting radioisotopes, such as 225Ac.

  In the past one year, the Nuclear Oncology Experts team at the Department of Nuclear Medicine at Fortis Memorial Research Institute has treated 30 new patients of Castrate Resistant Prostate Cancer (CRPC) with  Ac225 PSMA Therapy  (Targeted Alpha Therapy). And the results are similar to the results being achieved by most good Nuclear Medicine Centres across the world – 75-80% of the patients have shown evidence of a significant Radiological and Biochemical Response with prolonged duration of response. ADVERSE EFFECTS: The Ac225 PSMA Therapy is extremely well tolerated with minimal adverse effects that usually do not require any active management. The adverse effects usually experienced are fatigue in the immediate post-therapy, a transient mild drop in blood counts approximately three-weeks post-therapy and dry mouth. SOURCING OF Ac 225: The Ac225 used at the center is a highly purified form with no added carriers. It is approved by the European Medicines Association and also

According to the  World Cancer Research Fund , Prostate Cancer is not only one of the most common malignancy in men but also one of the most commonly occurring cancer overall. Prostate Cancer is also the fifth leading cause of death from cancer in men. Disease progression and metastatic spread signifies the beginning of a lethal form of the disease – metastatic castration resistant prostate cancer (mCRPCa). The incidence of prostate cancer increases proportionally with age, especially in men above 60 years of age. Studies have also shown that incidence of prostate cancer also depend on demographics and racial prevalence – prostate cancer has a low incidence in Asia (3-8 per 100,000 men per year), an intermediate incidence in Africa and Eastern Europe, and a higher incidence in North America and Western Europe. While conventional treatment modalities for localized prostate cancers include surgery, chemotherapy, cryotherapy, brachytherapy with radioactive seeds, and usage of external

  Cancer is an abnormal cellular growth in a specific body region that is able to spread internally and cover other areas. If left untreated, it causes a number of life-threatening conditions that may even lead to fatality. World Health Organization  (WHO) notes cancer to be the second leading cause of death. An estimated 9.6 million deaths have occurred due to it in 2018 alone. That amounts to 1 in every 6 losses of lives. What is Prostate Cancer? Prostate cancer refers to the development of cancer in the prostate gland of the male reproductive organ . Its growth rate is observed to be highly inconsistent, with a majority of it being slow to form while some manifesting at a fairly rapid pace. But the fact that it may spread out towards other body areas, specifically bones and lymph nodes, is proven to be conclusive. Symptoms of Prostate Cancer: Early Warning Signs Prostate cancer may prove to be hard to detect due to it having zero or faint traces of initial symptom occurr